GIP receptor
Supports glucose-dependent insulin signaling and nutrient-response pathways.
P—17 • Clinically established profile
Tirzepatide
A concise educational overview of a clinically established dual GIP and GLP-1 receptor agonist used in approved metabolic indications.
Name
Tirzepatide
Approved products include Mounjaro and Zepbound
- Scientific classification
- Synthetic long-acting dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist
- Library family
- Metabolic
- Research status
- Clinically established, with continuing research across metabolic, cardiovascular, kidney, liver, and sleep-related outcomes
- Regulatory status
- FDA approved under indication-specific Mounjaro and Zepbound labels for defined populations and uses
Compound overview
A dual-incretin peptide with established clinical applications.
Tirzepatide combines activity at the receptors for GIP and GLP-1, two naturally occurring incretin hormones involved in glucose-dependent insulin signaling, appetite, nutrient handling, and energy balance.
Approved products, populations, and indications should not be treated as interchangeable with compounded or unapproved formulations.
Mechanism under study
Coordinated dual-incretin signaling
Tirzepatide activates two metabolically relevant receptors within one peptide. Its clinical effects depend on the approved product, indication, patient population, and broader medical context.
GLP-1 receptor
Influences insulin release, glucagon regulation, appetite, food intake, and gastrointestinal signaling.
Integrated metabolic response
Combined signaling can improve glycemic control, reduce energy intake, and delay gastric emptying.
The delay in gastric emptying is greatest after initial exposure and can affect the absorption or clinical handling of other medications.
Current research areas
Questions under investigation
- Type 2 diabetes and glycemic control
- Obesity and long-term weight management
- Obstructive sleep apnea associated with obesity
- Cardiovascular and kidney outcomes
- Metabolic liver disease and related complications
Evidence summary
Evidence-supported clinical outcomes
- Glycemic control: Clinical trials demonstrate substantial reductions in HbA1c among people with type 2 diabetes.
- Weight management: SURMOUNT-1 reported average weight reductions of approximately 15% to 21% after 72 weeks, depending on the studied dose.
- Long-term weight maintenance: Zepbound is approved to reduce excess body weight and maintain weight reduction in qualifying adults.
- Obstructive sleep apnea: Trials demonstrated reductions in apnea and hypopnea events among adults with obesity and moderate-to-severe OSA.
- Cardiometabolic measures: Studies report changes in blood pressure, lipid measurements, insulin sensitivity, and other metabolic markers.
Benefits depend upon the approved product, indication, studied population, and individual clinical circumstances.
Educational notice
Education, not usage guidance.
This profile is provided for scientific education only. It is not medical advice, prescribing guidance, dosing information, or instructions for tirzepatide use. FDA-approved labeling includes a boxed warning concerning thyroid C-cell tumors observed in rodents and additional warnings involving severe gastrointestinal reactions, pancreatitis, gallbladder disease, kidney injury associated with dehydration, hypoglycemia in certain treatment combinations, hypersensitivity, and other clinically important risks.
Key scientific referencesComing soon
A curated primary-source reference list will be added during the next educational expansion.